Is BioVie Inc (BIVI) Stock a Good Investment?
Learn more about BioVie Inc's (BIVI) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2b clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Commentary & Analysis
Financial Summary
| Share Statistics | BIVI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.9 | $249.2 | 7% |
|
| Shares Out (Mil) | 7.9 | 53.9 | 18% |
|
| Institutional Ownership | 97.1% | 93.0% | 72% |
|
| Float (Mil) | 7.5 | 41.4 | 16% |
|
| Beta | 0.67 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 223 | 631 | 45% |
|
| Price Change (52-week) |
(28.0%) | 49.2% | 30% |
|
| Growth | BIVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | 29.9% | (10.1%) | 85% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.2%) | (15.7%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BIVI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($22) | ($44) | 23% |
|
| EPS (TTM) | ($3.052) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($33) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $5 | $175 | 6% |
|
| Valuation | BIVI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.06 | 2.42 | 26% |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BIVI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (123.3%) | (47.7%) | 4% |
|
| ROE | (150.8%) | (54.6%) | 6% |
|
| Liabilities to Assets | 27.9% | 29.3% | 19% |
|
| F-Score | 2 | 3 | 7% |
|
BioVie Inc. did not pass any screens on 10/5/2026.
